Indacaterol thalin Currently CI994 is in phase

Currently CI994 is in phase III clinical trials for lung cancer

Poliumoside exhibits greater inhibitory effects on rat lens aldose reductase(RLAR) with IC50 values of 8

Formula: C21H20ClF4N7

InChiKey: HKSZLNNOFSGOKW-FYTWVXJKSA-N

CAS Number: 677331-12-3

Indacaterol thalin Currently CI994 is in phaseIndacaterol is an ultra long acting beta adrenoceptor agonist developed by Novartis. It was approved by the European Medicines Agency (EMA) under the trade name Onbrez on November 30, 2009, and by the United States Food and Drug Administration (FDA), under the trade name Arcapta Neohaler, on July 1, 2011. It needs to be taken only once a day, unlike the related drugs formoterol and salmeterol. It is licensed only for the treatment of chronic